DE69738495T2 - Verfahren zur regulation der angiogenese - Google Patents

Verfahren zur regulation der angiogenese Download PDF

Info

Publication number
DE69738495T2
DE69738495T2 DE69738495T DE69738495T DE69738495T2 DE 69738495 T2 DE69738495 T2 DE 69738495T2 DE 69738495 T DE69738495 T DE 69738495T DE 69738495 T DE69738495 T DE 69738495T DE 69738495 T2 DE69738495 T2 DE 69738495T2
Authority
DE
Germany
Prior art keywords
cells
growth factor
angiogenesis
endothelial
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69738495T
Other languages
German (de)
English (en)
Other versions
DE69738495D1 (de
Inventor
Jeffrey M. Weston ISNER
Takayuki Arlington ASAHARA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caritas St Elizabeth Medical Center of Boston
St Elizabeths Medical Center of Boston Inc
Original Assignee
Caritas St Elizabeth Medical Center of Boston
St Elizabeths Medical Center of Boston Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caritas St Elizabeth Medical Center of Boston, St Elizabeths Medical Center of Boston Inc filed Critical Caritas St Elizabeth Medical Center of Boston
Publication of DE69738495D1 publication Critical patent/DE69738495D1/de
Application granted granted Critical
Publication of DE69738495T2 publication Critical patent/DE69738495T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0691—Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DE69738495T 1996-11-08 1997-11-06 Verfahren zur regulation der angiogenese Expired - Lifetime DE69738495T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US744882 1996-11-08
US08/744,882 US5980887A (en) 1996-11-08 1996-11-08 Methods for enhancing angiogenesis with endothelial progenitor cells
PCT/US1997/019935 WO1998019712A1 (en) 1996-11-08 1997-11-06 Methods for regulating angiogenesis

Publications (2)

Publication Number Publication Date
DE69738495D1 DE69738495D1 (de) 2008-03-20
DE69738495T2 true DE69738495T2 (de) 2008-08-28

Family

ID=24994332

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69738495T Expired - Lifetime DE69738495T2 (de) 1996-11-08 1997-11-06 Verfahren zur regulation der angiogenese

Country Status (7)

Country Link
US (2) US5980887A (https=)
EP (2) EP1618898A3 (https=)
JP (2) JP4628504B2 (https=)
AU (1) AU743267B2 (https=)
CA (1) CA2271690C (https=)
DE (1) DE69738495T2 (https=)
WO (1) WO1998019712A1 (https=)

Families Citing this family (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192198A1 (en) * 1998-04-21 2002-12-19 Elia James P. Method for growing human organs and suborgans
US20030157074A1 (en) * 1994-11-16 2003-08-21 Mitrani Eduardo N. Vitro micro-organs, and uses related thereto
US8075880B2 (en) * 1999-01-11 2011-12-13 Steward St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for regulating angiogenesis
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US6486133B1 (en) 1997-03-07 2002-11-26 The Wistar Institute Of Anatomy And Biology Methods for inducing localized vascular development and enhancing the repair of a wound in the mammamian dermis
US7507705B2 (en) * 1997-10-02 2009-03-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
US6749617B1 (en) * 1997-11-04 2004-06-15 Scimed Life Systems, Inc. Catheter and implants for the delivery of therapeutic agents to tissues
US7687057B2 (en) * 1998-01-09 2010-03-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem In vitro micro-organs, and uses related thereto
US6852533B1 (en) * 1998-01-23 2005-02-08 Cornell Research Foundation, Inc. Purified populations of stem cells
US20040228834A1 (en) * 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
US6676937B1 (en) * 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
WO1999045775A1 (en) * 1998-03-09 1999-09-16 St. Elizabeth's Medical Center Compositions and methods for modulating vascularization
US6482406B1 (en) 1999-03-26 2002-11-19 Duncan J. Stewart Cell-based gene therapy for the pulmonary system
US9585916B2 (en) 1999-03-26 2017-03-07 Northern Therapeutics Inc. Cell based therapy for the pulmonary system
CA2266805C (en) 1998-03-27 2015-04-28 An-Go-Gen Inc. Cell-based gene therapy in the treatment of pulmonary disorders
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US8197430B1 (en) 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
CA2336813A1 (en) 1998-07-10 2000-01-20 Victor J. Dzau Methods for implanting cells
US6677300B1 (en) * 1998-09-09 2004-01-13 Scios, Inc. Treatment of microvascular angiopathies
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
EP1568375A1 (en) * 1998-10-26 2005-08-31 Ludwig Institute For Cancer Research Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
WO2000024412A2 (en) * 1998-10-26 2000-05-04 Ludwig Institute For Cancer Research Use of vegf-c or vegf-d gene or protein to prevent restenosis
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
DE19850986A1 (de) * 1998-11-05 2000-05-25 Aventis Pharma Gmbh Die gentechnische Prägung von Zellen und ihre Verwendung zur Prophylaxe und Therapie von Erkrankungen
EP1144594A1 (en) 1998-11-24 2001-10-17 Regents Of The University Of Minnesota Transgenic circulating endothelial cells
US20040131601A1 (en) * 2000-03-30 2004-07-08 Foundry Networks, Inc., A Delaward Corporation Injection of bone marrow-derived cells and medium for angiogenesis
US6348050B1 (en) * 1999-04-30 2002-02-19 Medtronic, Inc. Infusion systems for creating microenvironments in a living body
US20030152562A1 (en) * 2001-10-23 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Vitro micro-organs, and uses related thereto
US20060127366A1 (en) * 1999-06-25 2006-06-15 Mitrani Eduardo N Method and device for inducing biological processes by micro-organs
US20050158289A1 (en) * 1999-07-07 2005-07-21 Simmons Paul J. Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammals
AUPQ147799A0 (en) * 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US7670628B2 (en) * 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US8062675B2 (en) 1999-07-07 2011-11-22 Angioblast Systems, Inc. Mesenchymal precursor cell
US20020193301A1 (en) 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
AU6920800A (en) * 1999-08-19 2001-03-13 Stem Cell Pharmaceuticals, Inc. Tgf-alpha polypeptides, functional fragments and methods of use therefor
BR9917500A (pt) * 1999-09-23 2002-05-21 An Go Gen Inc Terapia gênica baseada em célula para o sistema pulmonar
CN1182874C (zh) * 1999-10-29 2005-01-05 安增子摩祺株式会社 糖尿病性局部缺血疾病的基因治疗制剂
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
US9522217B2 (en) * 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) * 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20030229393A1 (en) * 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
AU2001245734A1 (en) 2000-03-15 2001-09-24 Orbus Medical Technologies Inc. Coating that promotes endothelial cell adherence
US20070055367A1 (en) * 2000-03-15 2007-03-08 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
US8460367B2 (en) * 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20030104977A1 (en) * 2000-03-31 2003-06-05 Ugo Ripamonti Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
US7166280B2 (en) * 2000-04-06 2007-01-23 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US9694038B2 (en) * 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US10281478B2 (en) 2000-04-06 2019-05-07 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20100303769A1 (en) * 2000-04-06 2010-12-02 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US20070111935A1 (en) * 2000-04-06 2007-05-17 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20050277576A1 (en) * 2000-04-06 2005-12-15 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US6800298B1 (en) * 2000-05-11 2004-10-05 Clemson University Biological lubricant composition and method of applying lubricant composition
MXPA02012067A (es) 2000-06-05 2004-08-19 Univ Columbia Identificacion y uso de celulas endoteliales precursoras derivadas de medula osea par mejorar la funcion del miocardio despues de dano isquemico.
WO2002008389A2 (en) * 2000-07-26 2002-01-31 Scimed Life Systems, Inc. Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
EP1383551B1 (en) * 2000-11-08 2010-07-14 Boston Scientific Limited Multilumen catheter and implants for the delivery of therapeutic agents to tissues
US7029209B2 (en) 2000-12-18 2006-04-18 Cardemon, Inc. Slidable boring tool with fine adjustment
US7824680B2 (en) * 2001-08-06 2010-11-02 The Regents Of The University Of California Methods for inhibiting angiogenesis
EP1420807A4 (en) * 2001-08-09 2005-08-17 Cornell Res Foundation Inc THROMBOZYTE GROWTH FACTOR FOR THE PROTECTION OF THE CARDIAL MYOKARD
AU2002331669A1 (en) * 2001-08-23 2003-03-10 The Wistar Institute Of Anatomy And Biology An organotypic intestinal culture and methods of use thereof
US20030054331A1 (en) * 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
US20040031067A1 (en) * 2001-10-11 2004-02-12 Meenhard Herlyn Regulation of human skin healing
US20040044403A1 (en) * 2001-10-30 2004-03-04 Joyce Bischoff Tissue-engineered vascular structures
JP4447916B2 (ja) * 2001-11-05 2010-04-07 メドジニックス・インコーポレイテッド 微小器官処理システム及びそれを用いた微小器官の製造方法
US8608661B1 (en) 2001-11-30 2013-12-17 Advanced Cardiovascular Systems, Inc. Method for intravascular delivery of a treatment agent beyond a blood vessel wall
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
US7585670B2 (en) * 2001-12-07 2009-09-08 Cytori Therapeutics, Inc. Automated methods for isolating and using clinically safe adipose derived regenerative cells
US7651684B2 (en) * 2001-12-07 2010-01-26 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
US20050008626A1 (en) * 2001-12-07 2005-01-13 Fraser John K. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US20050095228A1 (en) * 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US7595043B2 (en) * 2001-12-07 2009-09-29 Cytori Therapeutics, Inc. Method for processing and using adipose-derived stem cells
US20050048035A1 (en) 2001-12-07 2005-03-03 Fraser John K. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
US20060204556A1 (en) * 2001-12-07 2006-09-14 Cytori Therapeutics, Inc. Cell-loaded prostheses for regenerative intraluminal applications
US7514075B2 (en) * 2001-12-07 2009-04-07 Cytori Therapeutics, Inc. Systems and methods for separating and concentrating adipose derived stem cells from tissue
KR100930139B1 (ko) * 2001-12-07 2009-12-07 사이토리 테라퓨틱스, 인크. 처리된 리포애스퍼레이트 세포로 환자를 치료하기 위한시스템 및 방법
WO2006075986A1 (en) * 2005-01-10 2006-07-20 Macropore Biosurgery, Inc. Devices and methods for monitoring, managing, and servicing medical devices
US8404229B2 (en) * 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
EP1467746A4 (en) * 2001-12-20 2006-10-04 Macropore Inc SYSTEMS AND METHODS FOR TREATING PATIENTS WITH COLLAGEN-RICH MATERIAL EXTRACTED FROM ADIPOSE TISSUES
MXPA04006154A (es) * 2001-12-21 2004-11-01 Immunex Corp Celulas madre endoteliales, poblaciones y metodos para el aislamiento y uso de las mismas.
US20030139333A1 (en) * 2002-01-18 2003-07-24 Genetix Pharmaceuticals, Inc. Methods and compositions for promoting angiogenesis
US20040009146A1 (en) * 2002-02-26 2004-01-15 Osvaldo Podhajcer Anti-tumor vaccine and method
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US7361368B2 (en) 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
US20040009158A1 (en) * 2002-07-11 2004-01-15 Washington University Promotion of neovascularization using bone marrow-derived endothelial-progenitor cells
EP1563058A4 (en) * 2002-07-12 2005-12-28 Univ Singapore Haemangioblasts-Progenitor Cells
US20040052771A1 (en) * 2002-07-12 2004-03-18 Lim Sai Kiang Hemangioblast progenitor cells
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US20040037811A1 (en) * 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
WO2008121719A1 (en) * 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
US20040258670A1 (en) * 2002-12-05 2004-12-23 Case Western Reserve University Cell-based therapies for ischemia
US7060684B1 (en) 2002-12-16 2006-06-13 Quijano Rodolfo C Device for treating diabetes and methods thereof
US8940292B2 (en) 2003-01-28 2015-01-27 Wake Forest University Health Sciences Enhancement of angiogenesis to grafts using cells engineered to produce growth factors
US20040197310A1 (en) * 2003-02-12 2004-10-07 Sanberg Paul R. Compositions and methods for using umbilical cord progenitor cells in the treatment of myocardial infarction
EP1615996A4 (en) * 2003-03-27 2006-11-15 Texase A & M University System USES OF VEGETABLE TOTHELIC GROWTH FACTOR AND COLLAGEN INDUCIBLE PROTEIN TYPE I (VCIP)
US8038991B1 (en) 2003-04-15 2011-10-18 Abbott Cardiovascular Systems Inc. High-viscosity hyaluronic acid compositions to treat myocardial conditions
US8383158B2 (en) 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US20040247575A1 (en) * 2003-06-03 2004-12-09 Caplice Noel M. Smooth muscle progenitor cells
ES2633604T3 (es) * 2003-09-17 2017-09-22 Cytori Therapeutics, Inc. Métodos para usar células regenerativas derivadas de adiposo en el tratamiento de una enfermedad vascular periférica
US9403908B2 (en) * 2003-09-29 2016-08-02 The Regents Of The University Of California Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration
US20090118817A1 (en) * 2005-06-16 2009-05-07 Mayo Foundation For Medical Education And Research Magnetic Medical Apparatus, Kits, and Methods
US8465453B2 (en) * 2003-12-03 2013-06-18 Mayo Foundation For Medical Education And Research Kits, apparatus and methods for magnetically coating medical devices with living cells
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
JP2007217283A (ja) * 2004-03-30 2007-08-30 Niigata Tlo:Kk 血管新生促進剤および血管新生療法
TW200605910A (en) * 2004-04-30 2006-02-16 Orbus Medical Technologies Inc Medical device with coating for capturing genetically-altered cells and methods for using same
JP2007536936A (ja) 2004-05-14 2007-12-20 ベクトン・ディキンソン・アンド・カンパニー 幹細胞集団および使用方法
PL1759536T3 (pl) 2004-06-01 2011-10-31 Kwalata Trading Ltd Techniki in vitro z użyciem komórek macierzystych
CA2574186A1 (en) * 2004-08-13 2006-02-23 Medtronic, Inc. Isolation of endothelial progenitor cell subsets and methods for their use
KR20070085288A (ko) * 2004-09-24 2007-08-27 안지오블라스트 시스템스 인코퍼레이티드 간엽 전구세포의 증식 및/또는 생존성 증강 방법
CA2582567A1 (en) * 2004-10-07 2006-04-13 Stem Cell Therapeutics Corp. Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds
WO2006055743A2 (en) * 2004-11-18 2006-05-26 Franco, Wayne Compbination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20060110374A1 (en) * 2004-11-24 2006-05-25 Dudy Czeiger Method to accelerate stem cell recruitment and homing
US20060165667A1 (en) * 2004-12-03 2006-07-27 Case Western Reserve University Novel methods, compositions and devices for inducing neovascularization
US20090215782A1 (en) * 2005-04-18 2009-08-27 Carlo Foresta Use of PDE-5 Inhibitors for Endothelial Repair of Tissues Impaired by Trauma or Disease
US8828433B2 (en) * 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
FR2889200B1 (fr) * 2005-07-27 2008-01-04 Inst Vaisseaux Et Du Sang Ass Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
US7652922B2 (en) * 2005-09-30 2010-01-26 Mosaid Technologies Incorporated Multiple independent serial link memory
US20070100323A1 (en) * 2005-10-31 2007-05-03 Ludwig Florian N Facilitation of endothelialization by in situ surface modification
US8637005B2 (en) 2005-11-07 2014-01-28 Amorcyte, Inc. Compositions and methods of vascular injury repair
US20110076255A1 (en) 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
EP1951864B1 (en) * 2005-11-07 2014-05-07 Amorcyte, Inc. Compositions and methods of vascular injury repair
TW200734462A (en) 2006-03-08 2007-09-16 In Motion Invest Ltd Regulating stem cells
US7732190B2 (en) 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9242005B1 (en) * 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
EP2068897A1 (en) * 2006-10-03 2009-06-17 Medtronic, Inc. Endothelial progenitor cell compositions and neovascularization
WO2008085229A2 (en) * 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8741326B2 (en) 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
FR2909559B1 (fr) * 2006-12-06 2012-09-07 Inst Vaisseaux Et Du Sang Preparations cellulaires pour une utilisation comme agent stimulant la revascularisation
WO2008077094A2 (en) * 2006-12-19 2008-06-26 Children's Medical Center Corporation Methods for promoting neovascularization
US8137968B2 (en) * 2007-02-28 2012-03-20 The Board Of Trustees Of The University Of Illinois Selected endothelial progenitor cells and methods for use
EP2114422A1 (en) * 2007-03-02 2009-11-11 National University of Ireland, Galway Osteopontin for the prediction and treatment of cardiovascular diseases
US7632340B2 (en) * 2007-03-07 2009-12-15 Hamilton Beach Brands, Inc. Air purifier for removing particles or contaminants from air
EP2163250B1 (en) * 2007-05-18 2013-01-09 National University Corporation Asahikawa Medical University Anticancer therapy by transplanting vascular endothelial progenitor cells
AU2008265973A1 (en) * 2007-06-13 2008-12-24 Wake Forest University Health Sciences Methods of restoration of erectile function
US20090053208A1 (en) * 2007-08-20 2009-02-26 Medtronic Vascular, Inc. Methods and Systems for Improving Tissue Perfusion
CA2709398C (en) 2007-12-14 2017-11-07 The Cleveland Clinic Foundation Use of stromal cell-derived factor 1 for promoting wound healing
US11051733B2 (en) 2008-01-18 2021-07-06 Wake Forest University Health Sciences Isolating and purifying cells for therapy
US20090246179A1 (en) * 2008-02-11 2009-10-01 The Cleveland Clinic Foundation Method of treating myocardial injury
US20100028311A1 (en) * 2008-07-09 2010-02-04 Baxter International Inc. Using of scaffold comprising fibrin for delivery of stem cells
WO2010021993A1 (en) 2008-08-19 2010-02-25 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
RU2497532C2 (ru) * 2008-12-03 2013-11-10 Эморсайт, Инк. Композиции, улучшающие перфузию в области инфаркта и способы восстановления сосудистого повреждения
EP2418272A4 (en) 2009-04-07 2013-02-27 Nat University Corp Asahikawa Medical University NEW REVASCULARIZATION CELLS FROM MONONUCLEAR CELLS AND METHOD FOR DIFFERENTIATING INDICATION THEREFOR
AU2010242780B2 (en) 2009-05-01 2016-04-21 Puregraft Llc Systems, methods and compositions for optimizing tissue and cell enriched grafts
WO2011026041A2 (en) 2009-08-28 2011-03-03 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
KR20120100962A (ko) * 2009-10-02 2012-09-12 박스터 헬쓰케어 에스.에이. 신장 손상을 치료하는데 사용하기 위한 조혈 줄기 세포
ES2610241T3 (es) 2009-10-23 2017-04-26 Amorcyte, Inc. Composiciones y usos para el tratamiento de lesiones miocárdicas progresivas debidas a una insuficiencia vascular
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2012048276A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
NZ609567A (en) * 2010-11-05 2015-05-29 Transbio Ltd Markers of endothelial progenitor cells and uses thereof
WO2012075243A2 (en) 2010-12-01 2012-06-07 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
US9533010B2 (en) 2011-10-31 2017-01-03 Amorcyte, Llc Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
JP2015508101A (ja) 2012-02-21 2015-03-16 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｃｄ３４＋細胞を含む薬学的組成物
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
EP4314244B1 (en) 2021-03-23 2025-07-23 Terumo BCT, Inc. Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE68703T1 (de) 1984-02-08 1991-11-15 Cetus Corp Toxinkonjugate.
US4883755A (en) * 1987-10-28 1989-11-28 Thomas Jefferson University Method of reendothelializing vascular linings
JP2914692B2 (ja) * 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
US5612211A (en) * 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
ES2096750T3 (es) * 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
AU3429993A (en) * 1992-01-10 1993-08-03 Georgetown University A method of administering genetically engineered endothelial cells to sites of angiogenesis for effecting genetic therapy
US5536641A (en) * 1994-05-17 1996-07-16 Memorial Sloane Kittering Cancer Center Monoclonal antibody specific for vascular endothelial cell antigen endoglyx-1 and uses thereof for detection of, and isolation of, vascular endothelial cells
EP0781333A1 (en) * 1994-08-26 1997-07-02 Novartis AG (Novartis SA) (Novartis Inc.) Gene therapy for transplantation and inflammatory or thrombotic conditions
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US5874301A (en) * 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5688237A (en) * 1995-05-04 1997-11-18 Cedars-Sinai Medical Center Implantable catheter and method of use
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
AU1873097A (en) * 1996-02-14 1997-09-02 New England Deaconess Hospital Corporation Gene therapy of entothelial cells with anti-apoptotic proteins for transplantation and inflammatory conditions
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells

Also Published As

Publication number Publication date
JP2009197028A (ja) 2009-09-03
JP5424385B2 (ja) 2014-02-26
CA2271690C (en) 2011-09-13
CA2271690A1 (en) 1998-05-14
HK1023278A1 (en) 2000-09-08
JP2001503427A (ja) 2001-03-13
US5980887A (en) 1999-11-09
EP1618898A2 (en) 2006-01-25
EP0941125B1 (en) 2008-01-30
US6569428B1 (en) 2003-05-27
JP4628504B2 (ja) 2011-02-09
AU5243298A (en) 1998-05-29
DE69738495D1 (de) 2008-03-20
EP0941125A1 (en) 1999-09-15
WO1998019712A1 (en) 1998-05-14
EP1618898A3 (en) 2007-12-12
AU743267B2 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
DE69738495T2 (de) Verfahren zur regulation der angiogenese
EP1100878B1 (de) Verfahren zur herstellung von genetisch modifizierten cd34-negativen, adhärent wachsenden hämatopoietischen stammzellen
US20230149469A1 (en) Wound healing and tissue engineering
US9095580B2 (en) Compositions and methods for regulating angiogenesis
Yu et al. Overexpression of CXCR4 in mesenchymal stem cells promotes migration, neuroprotection and angiogenesis in a rat model of stroke
DE60132429T2 (de) Pluripotente aus von fettgewebe stammenden stromazellen erzeugte stammzellen und deren verwendung
Weller et al. Development and growth of mouse embryonic kidney in organ culture and modulation of development by soluble growth factor
DE69937347T2 (de) Regulierung der hämatopoietischen stammzelldifferenzierung durch verwendung von menschlichen mesenchymalen stammzellen
Corti et al. Chemotactic factors enhance myogenic cell migration across an endothelial monolayer
EP0893493A2 (de) Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
WO2013122950A1 (en) Nprcps, pfdncs and uses thereof
Bensadoun et al. Neuroprotective effect of interleukin‐6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome
KR20010071601A (ko) 뇌실막 신경 간세포 및 이의 분리 방법
CA2318571A1 (en) Methods of controlling cell differentiation and growth using a fusion protein and a drug
Migliaccio et al. Cell therapy: filling the gap between basic science and clinical trials October 15–17, 2001, Rome, Italy
HK1023278B (en) Methods for regulating angiogenesis
Mir et al. The Introduction of Basic Fibroblast Growth Factor Promotes Quadriceps Muscle Regeneration after Damage in Mice.
HK1082209A (en) Methods for regulating angiogenesis
Simeonova Generation of Defined Astrocytic Phenotypes from Human Pluripotent Stem Cells for Transplantation after Spinal Cord Injury
WO2000078931A2 (de) Neuronales zellmaterial, verwendung als transplantat und verfahren zu dessen herstellung
HK1222586B (en) Wound healing and tissue engineering
DE102006051623A1 (de) Verfahren und Stoffgemisch zur Verbesserung eines in vivo Genfransfers

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: STROHSCHAENK UND KOLLEGEN, 85521 OTTOBRUNN